Long-Term Outcomes With Isatuximab-Carfilzomib-Dexamethasone (Isa-Kd) in Relapsed Multiple Myeloma (MM) Patients (pts) With 1q21+Status: Updated Results from the Phase 3 IKEMA Study

被引：0

作者：

Facon, Thierry ^{[1
]}

Moreau, Philippe ^{[2
]}

Spicka, Ivan ^{[3
]}

Suzuki, Kenshi ^{[4
]}

Yong, Kwee ^{[5
]}

Mikhael, Joseph ^{[6
]}

Fukao, Taro ^{[7
]}

Bisht, Kamlesh ^{[7
]}

Armstrong, Nicole ^{[8
]}

Mace, Sandrine ^{[9
]}

Risse, Marie-Laure ^{[10
]}

Martin, Thomas ^{[11
]}

机构：

[1] Lille Univ Hosp, Dept Hematol, Lille, France

[2] Univ Hosp Hotel Dieu, Dept Hematol, Nantes, France

[3] Charles Univ & Gen Hosp, Fac Med 1, Dept Hematol, Prague, Czech Republic

[4] Japanese Red Cross Med Ctr, Myeloma Amyloidosis Ctr, Tokyo, Japan

[5] Univ Coll Hosp, Dept Haematol, London, England

[6] City Hope Canc Ctr, Translat Genom Res Inst, Phoenix, AZ USA

[7] Sanofi, Global Oncol, Cambridge, MA USA

[8] Sanofi, Global Med Affairs, Cambridge, MA USA

[9] Sanofi, Res & Dev, Chilly Mazarin, France

[10] Sanofi, Res & Dev, Vitry Sur Seine, France

[11] Univ Calif San Francisco, Med Ctr, San Francisco, CA USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

1q21; IKEMA; isatuximab; carfilzomib; dexamethasone; multiple myeloma; phase III;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MM-248

引用

页码：S484 / S485

页数：2

共 50 条

[31] FINAL RESULTS OF PHASE (PH) 1/2 STUDY OF CARFILZOMIB, POMALIDOMIDE, AND DEXAMETHASONE (KPD) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): A MULTI-CENTER MMRC STUDY
Jakubowiak, A. J.
Rosenbaum, C. A.
Stephens, L.
Kukreti, V.
Cole, C.
Zimmerman, T.
Reece, D.
Berdeja, J.
Severson, E.
Wolfe, B.
Major, S.
McDonnell, K.
Nam, J.
Turowski, A.
Griffith, K.
Zonder, J.
HAEMATOLOGICA, 2017, 102 : 271 - 271
[32] A Phase 2 Study of Elotuzumab (Elo) in Combination with Lenalidomide and Low-Dose Dexamethasone (Ld) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (R/R MM): Updated Results
Richardson, Paul G.
Jagannath, Sundar
Moreau, Philippe
Jakubowiak, Andrzej
Raab, Marc S.
Facon, Thierry
Vij, Ravi
White, Darrell J.
Reece, Donna
Benboubker, Lotfi
Zonder, Jeffrey A.
Deng, Wei
Kroog, Glenn
Singhal, Anil K.
Lonial, Sagar
BLOOD, 2012, 120 (21)
[33] Overall Survival of Relapsed/Refractory Multiple Myeloma Patients Treated with Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone: Results from the Phase 3 Endeavor Study According to Age Subgroup
Niesvizky, Ruben
Ludwig, Heinz
Spencer, Andrew
Goldschmidt, Hartmut
Pika, Tomas
Mateos, Maria-Victoria
Dimopoulos, Meletios A.
Zhou, Lifen
Kimballand, Amy S.
Facon, Thierry
BLOOD, 2017, 130
[34] Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study(vol 396, 186, 2020)
Dimopoulos, M.
Quach, H.
Mateos, M-, V
Landgren, Ola
Leleu, Xavier
Siegel, David
Weisel, Katja
Yang, Hui
Klippel, Zandra
Zahlten-Kumeli, Anita
Usmani, Saad Z.
LANCET, 2020, 396 (10249): : 466 - 466
[35] UPDATED RESULTS FOR BORTEZOMIB (BTZ)-NAIVE PATIENTS (PTS) ENROLLED IN PX-171-004, AN ONGOING OPEN-LABEL, PHASE (PH) 2 STUDY OF CARFILZOMIB (CFZ), IN RELAPSED MULTIPLE MYELOMA (MM)
Kaufman, J. L.
Vesole, D. H.
Stewart, A.
Jakubowiak, A. J.
Jagannath, S.
Kukreti, V.
Mcdonagh, K. T.
Alsina, M.
Reu, F. J.
Orlowski, R. Z.
Kunkel, L.
Le, M. H.
Vij, R.
Wang, M.
ANNALS OF ONCOLOGY, 2011, 22 : 200 - 201
[36] Interim results from ASPIRE, a randomized, open-label, multicenter phase 3 study evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma
Stewart, A. K.
Rajkumar, S. V.
Dimopoulos, M. A.
Mihaylov, G. G.
Goranova-Marinova, V.
Rajnics, P.
Suvorov, A.
Jakubowiak, A. J.
San-Miguel, J. F.
Zojwalla, N.
Moreau, P.
Palumbo, A.
BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 : 20 - 20
[37] Isatuximab in Combination with Lenalidomide and Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma: Updated Safety Run-in Results from the Randomized Phase 3 Ithaca Study
Mateos, Maria-Victoria
Rodriguez Otero, Paula
Koh, Youngil
Martinez-Lopez, Joaquin
Parmar, Gurdeep
Prince, H. Miles
Quach, Hang
Ribas, Paz
Hermansen, Emil
Hungria, Vania T. M.
Besisik, Sevgi Kalayoglu
Kim, Jin Seok
Leleu, Xavier
Peceliunas, Valdas
Schjesvold, Fredrik
Sevindik, Omur G.
Lavrova, Tatiana
Dubin, Franck
Devisme, Christine
Lepine, Lucie
Mace, Sandrine
Morisse, Mony
Ghobrial, Irene
BLOOD, 2022, 140 : 7317 - 7319
[38] Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)
Usmani, Saad Z.
Quach, Hang
Mateos, Maria-Victoria
Landgren, Ola
Leleu, Xavier
Siegel, David S.
Weisel, Katja
Yang, Hui
Klippel, Zandra K.
Zahlten-Kumeli, Anita
Dimopoulos, Meletios A.
BLOOD, 2019, 134
[39] Efficacy and Safety of Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Endeavor (NCT01568866)
Chng, Wee-Joo
Goldschmidt, Hartmut
Dimopoulos, Meletios A.
Moreau, Philippe
Joshua, Douglas
Palumbo, Antonio
Facon, Thierry
Ludwig, Heinz
Pour, Ludek
Niesvizky, Ruben
Oriol, Albert
Rosinol, Laura
Suvorov, Aleksandr
Gaidano, Gianluca
Pika, Tomas
Weisel, Katja
Goranova-Marinova, Vesselina
Gillenwater, Heidi H.
Mohamed, Nehal
Feng, Shibao
Hajek, Roman
BLOOD, 2015, 126 (23)
[40] LONG-TERM OUTCOMES OF LENALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE (RD) IN CHINESE PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): MM-024 EXTENDED ACCESS PROGRAM (EAP)
Cai, Z.
Jin, J.
Chen, F.
Zhou, D. -B.
Yu, L.
Ke, X.
Li, X.
Wu, D.
Meng, F.
DeMarco, D.
Zhang, J.
Mei, J.
Hou, J.
Du, X.
HAEMATOLOGICA, 2015, 100 : 508 - 509

← 1 2 3 4 5 →